Resources
102 Results (showing 11 - 20)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 4/24/2020 (updated 3/28/2024)
Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents
Posted 5/22/2020 (updated 3/28/2024)
Report details information and guidance for addressing substance use issues encountered during home visiting. Discusses substance use issues and the way home visiting can address those issues while supporting families. Features a number of questions and answers and includes discussion regarding home visiting in rural areas.
Posted 5/22/2020 (updated 3/28/2024)
To identify Finnegan Neonatal Abstinence Scoring Tool tems independently associated with the decision to use pharmacologic therapy and to simplify the FNAST while minimizing loss of information for the treatment decision.
Posted 6/12/2020 (updated 3/28/2024)
Mother & Baby Substance Exposure Toolkit Best Practices All Best Practices came as a part of the California Medication Assisted Treatment Expansion Project
Posted 6/15/2020 (updated 3/28/2024)
The Opioid Use Disorder, Pregnant Women and Neonatal Abstinence Syndrome (NAS): Addressing the Challenges (Part II) webinar took place on June 9, 2020.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 6/30/2020 (updated 3/28/2024)
This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.
Posted 7/17/2020 (updated 3/28/2024)
Prescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%–22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited.
Posted 8/24/2020 (updated 3/28/2024)
Lessons Learned From Listening Sessions With Five Tribes in Minnesota.
Posted 8/24/2020 (updated 3/28/2024)
Medications for opioid use disorder, including buprenorphine hydrochloride and methadone hydrochloride, are highly effective at improving outcomes for individuals with the disorder. For pregnant women, use of these medications also improves pregnancy outcomes, including the risk of preterm birth. Despite the known benefits of medications for opioid use disorder, many pregnant and nonpregnant women with the disorder are not receiving them.